DIPEPTIDYL PEPTIDASE-4 INHIBITORS - NEW POTENTIALS FOR TREATMENT OF TYPE 2 DIABETES MELLITUS: EXPERIENCE OF USE OF GALVUS MET IN REAL-LIFE CLINICAL PRACTICE IN MOSCOW


Cite item

Full Text

Abstract

The article shows the advantages of dipeptidyl peptidase-4 inhibitors (DPP-4) associated with their multifaceted and physiological effects on the basic pathogenetic mechanisms of this disease, especially when used in combination with metformin, in patients with type 2 diabetes mellitus (DM). In Russia, DPP-4 inhibitors vildagliptin (Galvus) and a fixed combination of vildagliptin + metformin (Galvus Met) are widely used. Preliminary results of the program Efficacy of Galvus Met in real-life clinical practice of endocrinologists started in Moscow are presented; it was shown that the use of this drug in DM2 patients significantly improves glycemic control, is well tolerated and has beneficial effect on body weight and blood pressure.

References

  1. Schweizer A, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007;24:955-961
  2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15(6):540-59.
  3. Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. М., 2010. C. 92.
  4. Дедов И.И., Шестакова М.В., Аметов А.С. и др. Проект "Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа" // Сахарный диабет, 2011. № 1. Т. 50. С. 95-105.
  5. Bosi E, et al. Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with Metformin. Diabetes Care 2007;30:890-95.
  6. Ahren B, Pacini G, et al. Improved meal-related b-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40.
  7. Bosi E, et al. Improved Blood Pressure (BP) Lowering in Hypertensive Patients (pts) with Type 2 Diabetes (T2DM) with Vildagliptin Combined with Metformin Compared with Metformin Alone. Presented at ADA, 22-26 June 2007.
  8. Fonseca V, Schweizer A, Baron MA, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55.
  9. Ferrannini E, et al. 52-week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2008.
  10. Garber A, et al. "Effects of Vildagliptin on Glucose Control in Patients with Type 2 Diabetes Inadequately Controlled with a Sulphonylurea". Diabetes, Obesity and Metabolism 2008;10:1326-463.
  11. Bosi E, et al. Vildagliptin plus metformin combination therapy provides
  12. superior glycaemic control to individual monotherapy in treatment-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:506-15.
  13. Bourdel-Marchasson I, SchweizerA, Dejager S. Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus Hospital Practice 2011;39(1):1-15
  14. Анциферов МБ. Клинические аспекты применения и-ДПП-4 в комбинации с метформином: преимущества для разных групп пациентов // Фарматека 2011. № 3 (216). С. 50-55
  15. Анциферов М.Б., Зилов А.В. Перспективы применения и-ДПП-4 при СД 2 типа: инициация и продолжение терапии // Фарматека 2010. № 16 (210). С. 12-17.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies